Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neuroscience Bulletin
Published in: Neuroscience Bulletin 5/2017

01-10-2017 | Review

Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson’s Disease

Authors: Tingting Tang, Yong Li, Qian Jiao, Xixun Du, Hong Jiang

Published in: Neuroscience Bulletin | Issue 5/2017

Login to get access

Abstract

The application of neurotrophic factors (NTFs) is a promising therapeutic strategy for neurodegenerative disorders such as Parkinson’s disease (PD). Many NTFs have been reported to enhance the survival, regeneration, and differentiation of neurons and to induce synaptic plasticity. However, because of their potential side-effects and low efficacy after clinical administration, more potent treatments for neurodegenerative disorders are being sought. Cerebral dopamine neurotrophic factor (CDNF), a newly-identified NTF homologous to mesencephalic astrocyte-derived NTF, is structurally and functionally different from other NTFs, providing new hope especially for PD patients. In various animal models of PD, CDNF is efficient in protecting and repairing dopaminergic neurons, and it inhibits endoplasmic reticulum stress, neuroinflammation, and apoptosis. Recent progress in all facets of CDNF research has enabled researchers to better understand its beneficial effects in the treatment of PD.
Literature
1.
Deister C, Schmidt CE. Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng 2006, 3: 172–179.CrossRefPubMed
2.
Rodrigues TM, Jeronimo-Santos A, Outeiro TF, Sebastiao AM, Diogenes MJ. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson’s disease. Drugs Aging 2014, 31: 239–261.CrossRefPubMed
3.
Lindholm P, Voutilainen MH, Lauren J, Peranen J, Leppanen VM, Andressoo JO, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448: 73–77.CrossRefPubMed
4.
Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 2003, 20: 173–188.CrossRefPubMed
5.
Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neurotrophic factor therapy for Parkinson’s disease. Prog Brain Res 2010, 184: 237–264.CrossRefPubMed
6.
Batla A, Tayim N, Pakzad M, Panicker JN. Treatment options for urogenital dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2016, 18: 45.CrossRefPubMedPubMedCentral
7.
Su YR, Wang J, Wu JJ, Chen Y, Jiang YP. Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its neuroprotection for the PC12 cells damaged by lactacystin. Neurosci Bull 2007, 23: 67–74.CrossRefPubMed
8.
Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, et al. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant 2012, 21: 1213–1223.CrossRefPubMed
9.
Nadella R, Voutilainen MH, Saarma M, Gonzalez-Barrios JA, Leon-Chavez BA, Jimenez JM, et al. Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. J Neuroinflammation 2014, 11: 209.CrossRefPubMedPubMedCentral
10.
Latge C, Cabral KM, de Oliveira GA, Raymundo DP, Freitas JA, Johanson L, et al. The solution structure and dynamics of full-length human cerebral dopamine neurotrophic factor and its neuroprotective role against alpha-synuclein oligomers. J Biol Chem 2015, 290: 20527–20540.CrossRefPubMedPubMedCentral
11.
Back S, Peranen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson’s disease. Brain Behav 2013, 3: 75–88.CrossRefPubMedPubMedCentral
12.
Parkash V, Lindholm P, Peranen J, Kalkkinen N, Oksanen E, Saarma M, et al. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng Des Sel 2009, 22: 233–241.CrossRefPubMed
13.
Hellman M, Arumae U, Yu LY, Lindholm P, Peranen J, Saarma M, et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J Biol Chem 2011, 286: 2675–2680.CrossRefPubMed
14.
Vimal P, PäIvi L, Johan PN, Nisse K, Esko O, Mart S, et al. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng Des Sel 2009, 22: 233–241.CrossRef
15.
Lindahl M, Saarma M, Lindholm P. Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential. Neurobiol Dis 2017, 97: 90–102.CrossRefPubMed
16.
Lohoff FW, Bloch PJ, Ferraro TN, Berrettini WH, Pettinati HM, Dackis CA, et al. Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence. Neurosci Lett 2009, 453: 199–203.CrossRefPubMedPubMedCentral
17.
Apostolou A, Shen Y, Liang Y, Luo J, Fang S. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res 2008, 314: 2454–2467.CrossRefPubMed
18.
Holtz WA, O'Malley KL. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 2003, 278: 19367–19377.CrossRefPubMed
19.
Gang C, Bower KA, Cuiling M, Shengyun F, Thiele CJ, Jia L. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18: 1162–1164.
20.
Yusuke S, Kohsuke T, Hidenori I. The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med 2006, 6: 87–97.CrossRef
21.
Lindholm P, Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev Neurobiol 2010, 70: 360–371.PubMed
22.
Lindstrom R, Lindholm P, Kallijarvi J, Yu LY, Piepponen TP, Arumae U, et al. Characterization of the structural and functional determinants of MANF/CDNF in Drosophila in vivo model. PLoS One 2013, 8: e73928.CrossRefPubMedPubMedCentral
23.
Liu H, Zhao C, Zhong L, Liu J, Zhang S, Cheng B, et al. Key subdomains in the C-terminal of cerebral dopamine neurotrophic factor regulate the protein secretion. Biochem Biophys Res Commun 2015, 465: 427–432.CrossRefPubMed
24.
Choi JM, Hong JH, Chae MJ, Ngyuen PH, Kang HS, Ma HI, et al. Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease. Neurosci Lett 2011, 493: 97–101.CrossRefPubMed
25.
Sun ZP, Gong L, Huang SH, Geng Z, Cheng L, Chen ZY. Intracellular trafficking and secretion of cerebral dopamine neurotrophic factor in neurosecretory cells. J Neurochem 2011, 117: 121–132.CrossRefPubMed
26.
Palgi M, Lindstrom R, Peranen J, Piepponen TP, Saarma M, Heino TI. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc Natl Acad Sci U S A 2009, 106: 2429–2434.CrossRefPubMedPubMedCentral
27.
Niles LP, Sathiyapalan A, Bahna S, Kang NH, Pan Y. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol 2012, 15: 1343–1350.CrossRefPubMed
28.
Almutawaa W, Kang NH, Pan Y, Niles LP. Induction of neurotrophic and differentiation factors in neural stem cells by valproic acid. Basic Clin Pharmacol Toxicol 2014, 115: 216–221.CrossRefPubMed
29.
Lindholm P, Peranen J, Andressoo JO, Kalkkinen N, Kokaia Z, Lindvall O, et al. MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci 2008, 39: 356–371.CrossRefPubMed
30.
31.
Tsybko AS, Ilchibaeva TV, Kulikov AV, Kulikova EA, Krasnov IB, Sychev VN, et al. Effect of microgravity on glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor gene expression in the mouse brain. J Neurosci Res 2015, 93: 1399–1404.CrossRefPubMed
32.
Tadimalla A, Belmont PJ, Thuerauf DJ, Glassy MS, Martindale JJ, Gude N, et al. Mesencephalic astrocyte-derived neurotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart. Circ Res 2008, 103: 1249–1258.CrossRefPubMedPubMedCentral
33.
34.
Glembotski CC, Thuerauf DJ, Huang C, Vekich JA, Gottlieb RA, Doroudgar S. Mesencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic reticulum calcium depletion. J Biol Chem 2012, 287: 25893–25904.CrossRefPubMedPubMedCentral
35.
36.
Huang J, Chen C, Gu H, Li C, Fu X, Jiang M, et al. Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating GRP78 in SH-SY5Y cells. Cell Biol Int 2016, 40: 803–811.CrossRefPubMed
37.
Chen L, Feng L, Wang X, Du J, Chen Y, Yang W, et al. Mesencephalic astrocyte-derived neurotrophic factor is involved in inflammation by negatively regulating the NF-kappaB pathway. Sci Rep 2015, 5: 8133.CrossRefPubMedPubMedCentral
38.
Zhou C, Xiao C, Commissiong JW, Krnjevic K, Ye JH. Mesencephalic astrocyte-derived neurotrophic factor enhances nigral gamma-aminobutyric acid release. Neuroreport 2006, 17: 293–297.CrossRefPubMed
39.
Voutilainen MH, Back S, Peranen J, Lindholm P, Raasmaja A, Mannisto PT, et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson’s disease. Exp Neurol 2011, 228: 99–108.CrossRefPubMed
40.
Kemppainen S, Lindholm P, Galli E, Lahtinen HM, Koivisto H, Hamalainen E, et al. Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer’s disease as well as in wild-type mice. Behav Brain Res 2015, 291: 1–11.CrossRefPubMed
41.
Zhou W, Chang L, Fang Y, Du Z, Li Y, Song Y, et al. Cerebral dopamine neurotrophic factor alleviates Abeta25-35-induced endoplasmic reticulum stress and early synaptotoxicity in rat hippocampal cells. Neurosci Lett 2016, 633: 40–46.CrossRefPubMed
42.
Ma CH, Omura T, Cobos EJ, Latremoliere A, Ghasemlou N, Brenner GJ, et al. Accelerating axonal growth promotes motor recovery after peripheral nerve injury in mice. J Clin Invest 2011, 121: 4332–4347.CrossRefPubMedPubMedCentral
43.
Shakhbazau A, Martinez JA, Xu QG, Kawasoe J, van Minnen J, Midha R. Evidence for a systemic regulation of neurotrophin synthesis in response to peripheral nerve injury. J Neurochem 2012, 122: 501–511.CrossRefPubMed
44.
Fernández A, Guzmán S, Cruz Y, Zamorano P. Construction of bicistronic lentiviral vectors for tracking the expression of CDNF in transduced cells. Plasmid 2014, 76c: 15–23.
45.
Yi L, Lin N, Hua Z, Wen Z, Yuan-Qiang Z, Shuai-Shuai W, et al. Conserved dopamine neurotrophic factor-transduced mesenchymal stem cells promote axon regeneration and functional recovery of injured sciatic nerve. Plos One 2014, 9: e110993–e110993.CrossRef
46.
Cheng L, Liu Y, Zhao H, Zhang W, Guo YJ, Nie L. Lentiviral-mediated transfer of CDNF promotes nerve regeneration and functional recovery after sciatic nerve injury in adult rats. Biochem Biophys Res Commun 2013, 440: 330–335.CrossRefPubMed
47.
Garea-Rodriguez E, Eesmaa A, Lindholm P, Schlumbohm C, Konig J, Meller B, et al. Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson’s disease. PLoS One 2016, 11: e0149776.CrossRefPubMedPubMedCentral
48.
Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004, 62: 1568–1572.CrossRefPubMed
49.
Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014, 75: 351–362.CrossRefPubMed
50.
Hoffer BJ. Commentary on chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson’s disease. Merja H. Voutilainen et al. Exp Neurol 2011, 230: 162–166.CrossRefPubMed
51.
Domanskyi A, Saarma M, Airavaara M. Prospects of neurotrophic factors for Parkinson’s disease: comparison of protein and gene therapy. Hum Gene Ther 2015, 26: 550–559.CrossRefPubMed
52.
Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 2007, 82: 1083–1094.CrossRefPubMed
53.
Bohn MC. Motoneurons crave glial cell line-derived neurotrophic factor. Exp Neurol 2004, 190: 263–275.CrossRefPubMed
54.
Tomac A, Widenfalk J, Lin LF, Kohno T, Ebendal T, Hoffer BJ, et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci U S A 1995, 92: 8274–8278.CrossRefPubMedPubMedCentral
55.
Rocha SM, Cristovao AC, Campos FL, Fonseca CP, Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis 2012, 47: 407–415.CrossRefPubMed
56.
Cheng L, Zhao H, Zhang W, Liu B, Liu Y, Guo Y, et al. Overexpression of conserved dopamine neurotrophic factor (CDNF) in astrocytes alleviates endoplasmic reticulum stress-induced cell damage and inflammatory cytokine secretion. Biochem Biophys Res Commun 2013, 435: 34–39.CrossRefPubMed
57.
Zhao H, Cheng L, Liu Y, Zhang W, Maharjan S, Cui Z, et al. Mechanisms of anti-inflammatory property of conserved dopamine neurotrophic factor: inhibition of JNK signaling in lipopolysaccharide-induced microglia. J Mol Neurosci 2014, 52: 186–192.CrossRefPubMed
58.
Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis 2014, 42 Suppl 3: S125–152.PubMed
59.
Hosoi T, Ozawa K. Endoplasmic reticulum stress in disease: mechanisms and therapeutic opportunities. Clin Sci (Lond) 2010, 118: 19–29.CrossRef
60.
Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, David R, Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. J Neurosci 2002, 22: 10690–10698.PubMed
61.
Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ 2006, 13: 385–392.CrossRefPubMed
62.
Liu H, Tang X, Gong L. Mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor: New endoplasmic reticulum stress response proteins. Eur J Pharmacol 2015, 750: 118–122.CrossRefPubMed
63.
Mei JM, Niu CS. Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation. Neurol Sci 2014, 35: 1275–1280.CrossRefPubMed
64.
Mei J, Niu C. Protective and reversal effects of conserved dopamine neurotrophic factor on PC12 cells following 6-hydroxydopamine administration. Mol Med Rep 2015, 12: 297–302.CrossRefPubMed
65.
Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 2003, 5: 320–329.CrossRefPubMed
66.
Xu H, Belkacemi L, Jog M, Parrent A, Hebb MO. Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson’s disease. FASEB J 2013, 27: 4157–4168.CrossRefPubMed
67.
Mei J, Niu C. Effects of engineered conserved dopamine neurotrophic factor-expressing bone marrow stromal cells on dopaminergic neurons following 6-OHDA administrations. Mol Med Rep 2015, 11: 1207–1213.CrossRefPubMed
68.
Jiaming M, Niu C. Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson’s disease. Neurol Sci 2015, 36: 281–287.CrossRefPubMed
69.
Zhao H, Cheng L, Du X, Hou Y, Liu Y, Cui Z, et al. Transplantation of cerebral dopamine neurotrophic factor transducted BMSCs in contusion spinal cord injury of rats: promotion of nerve regeneration by alleviating neuroinflammation. Mol Neurobiol 2016, 53: 187–199.CrossRefPubMed
70.
Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson’s disease. Neurobiol Aging 2013, 34: 35–61.CrossRefPubMed
71.
Lim ST, Airavaara M, Harvey BK. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 2010, 61: 14–26.CrossRefPubMed
72.
Ren X, Zhang T, Gong X, Hu G, Ding W, Wang X. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol 2013, 248: 148–156.CrossRefPubMed
73.
Fernandez A, Guzman S, Cruz Y, Zamorano P. Construction of bicistronic lentiviral vectors for tracking the expression of CDNF in transduced cells. Plasmid 2014, 76: 15–23.CrossRefPubMed
74.
Cordero-Llana O, Houghton BC, Rinaldi F, Taylor H, Yanez-Munoz RJ, Uney JB, et al. Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson’s disease. Mol Ther 2015, 23: 244–254.CrossRefPubMed
Metadata
Title
Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson’s Disease
Authors
Tingting Tang
Yong Li
Qian Jiao
Xixun Du
Hong Jiang
Publication date
01-10-2017
Publisher
Springer Singapore
Published in
Neuroscience Bulletin / Issue 5/2017
Print ISSN: 1673-7067
Electronic ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-017-0123-4

Other articles of this Issue 5/2017

Neuroscience Bulletin 5/2017 Go to the issue

Original Article

Peripheral Lymphocyte Subsets as a Marker of Parkinson’s Disease in a Chinese Population

Review

Region-Specific Iron Measured by MRI as a Biomarker for Parkinson’s Disease

Review

Can Biomarkers Help the Early Diagnosis of Parkinson’s Disease?

Review

Transcription Factors: Potential Cell Death Markers in Parkinson’s Disease

Report

Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinson’s Disease

Review

Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson’s Disease